Proteogenomic studies on cancer drug resistance: towards biomarker discovery and target identification

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
   PubMed Web of Science ®Google Scholar
• McDermott JE, Wang J, Mitchell H, et al. Challenges in biomarker discovery: combining expert insights with statistical analysis of complex omics data. Expert Opin Med Diagn. 2013;7(1):37–51.
   PubMedGoogle Scholar
• Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976;455(1):152–162.
   PubMed Web of Science ®Google Scholar
• Nesvizhskii AI. A survey of computational methods and error rate estimation procedures for peptide and protein identification in shotgun proteomics. J Proteomics. 2010;73(11):2092–2123.
   PubMed Web of Science ®Google Scholar
• Lawrence MS, Stojanov P, Mermel CH, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014;505(7484):495–501.
   PubMed Web of Science ®Google Scholar
• Helmy M, Sugiyama N, Tomita M, et al. Onco-proteogenomics: a novel approach to identify cancer-specific mutations combining proteomics and transcriptome deep sequencing. Genome Biol. 2010;11(Suppl 1):P17.
   Google Scholar
• Ma B, Johnson R. De novo sequencing and homology searching. Mol Cell Proteomics. 2012;11(2):O111 014902.
   PubMed Web of Science ®Google Scholar
• Dasari S, Chambers MC, Slebos RJ, et al. TagRecon: high-throughput mutation identification through sequence tagging. J Proteome Res. 2010;9(4):1716–1726.
   PubMed Web of Science ®Google Scholar
• Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–421.
   PubMed Web of Science ®Google Scholar
• Turke AB, Zejnullahu K, Wu YL, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell. 2010;17(1):77–88.
   PubMed Web of Science ®Google Scholar
• Lin L, Bivona TG. Mechanisms of resistance to epidermal growth factor receptor inhibitors and novel therapeutic strategies to overcome resistance in NSCLC patients. Chemother Res Pract. 2012;817297:2012.
   Google Scholar
• Bhang HE, Ruddy DA, Krishnamurthy Radhakrishna V. et al. Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Nat Med. 2015;21(5):440–448.
   PubMed Web of Science ®Google Scholar
• Jaffe JD, Berg HC, Church GM. Proteogenomic mapping as a complementary method to perform genome annotation. Proteomics. 2004;4(1):59–77.
   PubMed Web of Science ®Google Scholar
• Menschaert G, Fenyo D. Proteogenomics from a bioinformatics angle: a growing field. Mass Spectrom Rev. 2015. doi:10.1002/mas.21483.
   PubMed Web of Science ®Google Scholar
• Nesvizhskii AI. Proteogenomics: concepts, applications and computational strategies. Nat Methods. 2014;11(11):1114–1125.
   PubMed Web of Science ®Google Scholar
• Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet. 2009;10(1):57–63.
   PubMed Web of Science ®Google Scholar
• Alfaro JA, Sinha A, Kislinger T, et al. Onco-proteogenomics: cancer proteomics joins forces with genomics. Nat Methods. 2014;11(11):1107–1113.
   PubMed Web of Science ®Google Scholar
• Wicki A, Mandala M, Massi D, et al. Acquired resistance to clinical cancer therapy: a twist in physiological signaling. Physiol Rev. 2016;96(3):805–829.
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Lavi O, Hall MD, et al. Toward a better understanding of the complexity of cancer drug resistance. Annu Rev Pharmacol Toxicol. 2016;56:85–102.
   PubMed Web of Science ®Google Scholar
• Omenn GS, Yocum AK, Menon R. Alternative splice variants, a new class of protein cancer biomarker candidates: findings in pancreatic cancer and breast cancer with systems biology implications. Dis Markers. 2009;28(4):241–251.
   Web of Science ®Google Scholar
• Sheynkman GM, Shortreed MR, Cesnik AJ, et al. Proteogenomics: integrating next-generation sequencing and mass spectrometry to characterize human proteomic variation. Annu Rev Anal Chem (Palo Alto Calif). 2016;9(1):521–545.
   PubMed Web of Science ®Google Scholar
• Castellana N, Bafna V. Proteogenomics to discover the full coding content of genomes: a computational perspective. J Proteomics. 2010;73(11):2124–2135.
   PubMed Web of Science ®Google Scholar
• Locard-Paulet M, Pible O, Gonzalez De Peredo A, et al. Clinical implications of recent advances in proteogenomics. Expert Rev Proteomics. 2016;13(2):185–199.
   PubMed Web of Science ®Google Scholar
• Ruggles KV, Tang Z, Wang X, et al. An analysis of the sensitivity of proteogenomic mapping of somatic mutations and novel splicing events in cancer. Mol Cell Proteomics. 2016;15(3):1060–1071.
   PubMed Web of Science ®Google Scholar
• Huang CH, Kuo CJ, Liang SS, et al. Onco-proteogenomics identifies urinary S100A9 and GRN as potential combinatorial biomarkers for early diagnosis of hepatocellular carcinoma. BBA Clinical. 2015;3:205–213.
   PubMed Web of Science ®Google Scholar
• Yeom J, Kabir MH, Lim B, et al. A proteogenomic approach for protein-level evidence of genomic variants in cancer cells. Sci Rep. 2016;6:35305.
   PubMed Web of Science ®Google Scholar
• Mann M, Kulak NA, Nagaraj N, et al. The coming age of complete, accurate, and ubiquitous proteomes. Mol Cell. 2013;49(4):583–590.
   PubMed Web of Science ®Google Scholar
• Bensimon A, Heck AJ, Aebersold R. Mass spectrometry-based proteomics and network biology. Annu Rev Biochem. 2012;81:379–405.
   PubMed Web of Science ®Google Scholar
• Ahrens CH, Brunner E, Qeli E, et al. Generating and navigating proteome maps using mass spectrometry. Nat Rev Mol Biol. 2010;11(11):789–801.
   PubMed Web of Science ®Google Scholar
• Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011;39(suppl_1):D945– D950.
   PubMed Web of Science ®Google Scholar
• Kim N, Shin S, Lee S. ECgene: genome-based EST clustering and gene modeling for alternative splicing. Genome Res. 2005;15(4):566–576.
   PubMed Web of Science ®Google Scholar
• Lane L, Argoudpuy G, Britan A, et al. neXtProt: a knowledge platform for human proteins. Nucleic Acids Res. 2011;40(Database issue):D76–83.
   PubMedGoogle Scholar
• Kim P, Yoon S, Kim N, et al. ChimerDB 2.0—a knowledgebase for fusion genes updated. Nucleic Acids Res. 2010;38(suppl_1):81–85.
   Web of Science ®Google Scholar
• Amberger J, Bocchini CA, Scott AF, et al. McKusick’s Online Mendelian Inheritance in Man (OMIM®). Nucleic Acids Res. 2009;37(suppl_1):793–796.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N, Weinstein JN, Collisson EA, et al. The cancer genome atlas pan-cancer analysis project. Nat Genet. 2013;45(10):1113–1120.
   PubMed Web of Science ®Google Scholar
• Park H, Bae J, Kim H, et al. Compact variant-rich customized sequence database and a fast and sensitive database search for efficient proteogenomic analyses. Proteomics. 2014;14(23–24):2742–2749.
   PubMed Web of Science ®Google Scholar
• Sun H, Chen C, Shi M, et al. Integration of mass spectrometry and RNA-Seq data to confirm human ab initio predicted genes and lncRNAs. Proteomics. 2014;14(23–24):2760–2768.
   PubMed Web of Science ®Google Scholar
• Ucciferri N, Rocchiccioli S. Proteomics techniques for the detection of translated pseudogenes. Methods Mol Biol. 2014;1167:187–195.
   PubMedGoogle Scholar
• Brosch M, Saunders GI, Frankish A, et al. Shotgun proteomics aids discovery of novel protein-coding genes, alternative splicing, and “resurrected” pseudogenes in the mouse genome. Genome Res. 2011;21(5):756–767.
   PubMed Web of Science ®Google Scholar
• Li HD, Menon R, Omenn GS, et al. Revisiting the identification of canonical splice isoforms through integration of functional genomics and proteomics evidence. Proteomics. 2014;14(23–24):2709–2718.
   PubMed Web of Science ®Google Scholar
• Edwards NJ. Novel peptide identification from tandem mass spectra using ESTs and sequence database compression. Mol Syst Biol. 2007;3(1):102.
   PubMed Web of Science ®Google Scholar
• Ning K, Fermin D, Nesvizhskii AI. Computational analysis of unassigned high-quality MS/MS spectra in proteomic data sets. Proteomics. 2010;10(14):2712.
   PubMed Web of Science ®Google Scholar
• Li XH, Li C, Xiao ZQ. Proteomics for identifying mechanisms and biomarkers of drug resistance in cancer. J Proteomics. 2011;74(12):2642–2649.
   PubMed Web of Science ®Google Scholar
• Ulrich Omasits MQ, Stekhoven DJ, Fortes C, et al. Directed shotgun proteomics guided by saturated RNA-seq identifies a complete expressed prokaryotic proteome. Genome Res. 2013;23(11):1916–1927.
   Google Scholar
• Kim MS, Pinto SM, Getnet D, et al. A draft map of the human proteome. Nature. 2014;509(7502):575–581.
   PubMed Web of Science ®Google Scholar
• Wilhelm M, Schlegl J, Hahne H, et al. Mass-spectrometry-based draft of the human proteome. Nature. 2014;509(7502):582.
   PubMed Web of Science ®Google Scholar
• Wu P, Zhang H, Lin W, et al. Discovery of novel genes and gene isoforms by integrating transcriptomic and proteomic profiling from mouse liver. J Proteome Res. 2014;13(5):2409–2419.
   PubMed Web of Science ®Google Scholar
• Shanmugam A, Yocum AK, Nesvizhskii AI. Utility of RNA-seq and GPMDB Protein observation frequency for improving the sensitivity of protein identification by tandem MS.  J Proteome Res. 2014;13(9):4113–4119.
   Google Scholar
• Crappé J, Ndah E, Koch A, et al. PROTEOFORMER: deep proteome coverage through ribosome profiling and MS integration. Nucleic Acids Res. 2015;43(5):e29.
   PubMed Web of Science ®Google Scholar
• Menschaert G, Fenyö D. Proteogenomics from a bioinformatics angle: a growing field. Mass Spectrom Rev. 2015. doi:10.1002/mas.21483.
   PubMed Web of Science ®Google Scholar
• Tanner S, Shu H, Frank A, et al. InsPecT: identification of posttranslationally modified peptides from tandem mass spectra. Anal Chem. 2005;77(14):4626–4639.
   PubMed Web of Science ®Google Scholar
• Castellana NE, Pham V, Arnott D, et al. Template proteogenomics: sequencing whole proteins using an imperfect database. Mol Cell Proteomics Mcp. 2010;9(6):1260.
   PubMed Web of Science ®Google Scholar
• Saeed F. Big data proteogenomics and high performance computing: challenges and opportunities. In: IEEE global conference on signal and information processing. 2015. p. 141–145.
   Google Scholar
• Geer LY, Markey SP, Kowalak JA, et al. Open mass spectrometry search algorithm. J Proteome Res. 2004;3(5):958–964.
   PubMed Web of Science ®Google Scholar
• Craig R, Beavis RC. TANDEM: matching proteins with tandem mass spectra. Bioinformatics. 2004;20(9):1466–1467.
   PubMed Web of Science ®Google Scholar
• Vaudel M, Barsnes H, Berven FS, et al. SearchGUI: an open-source graphical user interface for simultaneous OMSSA and X!Tandem searches. Proteomics. 2011;11(5):996.
   PubMed Web of Science ®Google Scholar
• Castellana NE, Shen Z, He Y, et al. An automated proteogenomic method uses mass spectrometry to reveal novel genes in Zea mays. Mol Cell Proteomics. 2014;13(1):157–167.
   PubMed Web of Science ®Google Scholar
• Woo S, Cha SW, Na S, et al. Proteogenomic strategies for identification of aberrant cancer peptides using large-scale next-generation sequencing data. Proteomics. 2014;14(23–24):2719–2730.
   PubMed Web of Science ®Google Scholar
• Sanders WS, Wang N, Bridges SM, et al. The proteogenomic mapping tool. BMC Bioinformatics. 2011;12(1):115.
   PubMed Web of Science ®Google Scholar
• Ferro M, Tardif M, Reguer E, et al. PepLine: a software pipeline for high-throughput direct mapping of tandem mass spectrometry data on genomic sequences. J Proteome Res. 2008;7(5):1873–1883.
   PubMed Web of Science ®Google Scholar
• Menschaert G, Vandekerckhove TTM, Baggerman G, et al. A hybrid, de novo based, genome-wide database search approach applied to the sea urchin neuropeptidome. J Proteome Res. 2010;9(2):990–996.
   PubMed Web of Science ®Google Scholar
• Kuhring M, Renard BY. iPiG: integrating peptide spectrum matches into genome browser visualizations. PLoS One. 2012;7(12):e50246.
   PubMed Web of Science ®Google Scholar
• Peterson ES, Mccue LA, Schrimperutledge AC, et al. VESPA: software to facilitate genomic annotation of prokaryotic organisms through integration of proteomic and transcriptomic data. BMC Genomics. 2012;13(1):1–13.
   PubMed Web of Science ®Google Scholar
• Brouwer RWW. MINOMICS: visualizing prokaryote transcriptomics and proteomics data in a genomic context. Bioinformatics. 2009;25(1):139–140.
   PubMed Web of Science ®Google Scholar
• Kumar D, Dash D. Proteogenomic tools and approaches to explore protein coding landscapes of eukaryotic genomes. Adv Exp Med Biol. 2016;926:1–10.
   PubMed Web of Science ®Google Scholar
• Helmy M, Tomita M, Ishihaha Y, et al. Peptide identification by searching large-scale tandem mass spectra against large databases: bioinformatics methods in proteogenomics. Genes. 2012;6(1):76–85.
   Google Scholar
• Risk BA, Spitzer WJ, Giddings MC. Peppy: proteogenomic search software. J Proteome Res. 2013;12(6):3019–3025.
   PubMed Web of Science ®Google Scholar
• Jagtap PD, Johnson JE, Onsongo G, et al. Flexible and accessible workflows for improved proteogenomic analysis using the Galaxy framework. J Proteome Res. 2014;13(12):5898–5908.
   PubMed Web of Science ®Google Scholar
• Ghali F, Krishna R, Perkins S, et al. ProteoAnnotator–open source proteogenomics annotation software supporting PSI standards. Proteomics. 2014;14(23–24):2731–2741.
   PubMed Web of Science ®Google Scholar
• Nagaraj SH, Waddell N, Madugundu AK, et al. PGTools: a Software Suite for Proteogenomic Data Analysis and Visualization. J Proteome Res. 2015;14(5):2255–2266.
   PubMed Web of Science ®Google Scholar
• Krasnov GS, Dmitriev AA, Kudryavtseva AV, et al. PPLine: an automated pipeline for SNP, SAP, and splice variant detection in the context of proteogenomics. J Proteome Res. 2015;14(9):3729–3737.
   PubMed Web of Science ®Google Scholar
• Kumar D, Yadav AK, Jia X, et al. Integrated transcriptomic-proteomic analysis using a proteogenomic workflow refines rat genome annotation. Mol Cell Proteomics. 2016;15(1):329–339.
   PubMed Web of Science ®Google Scholar
• Khatun J, Yu Y, Wrobel JA, et al. Whole human genome proteogenomic mapping for ENCODE cell line data: identifying protein-coding regions. BMC Genomics. 2013;14(1):141.
   PubMed Web of Science ®Google Scholar
• Castellana NE, Payne SH, Shen Z, et al. Discovery and revision of textitArabidopsis genes by proteogenomics. Proc Natl Acad Sci U S A. 2008;105(52):21034–21038.
   PubMed Web of Science ®Google Scholar
• Tanner S, Shen Z, Ng J, et al. Improving gene annotation using peptide mass spectrometry. Genome Res. 2007;17(2):231–239.
   PubMed Web of Science ®Google Scholar
• Tanner S, Shu H, Frank A, et al. InsPecT: identification of posttranslationally modified peptides from tandem mass spectra. Anal Chem. 2005;77(14):4626–4639.
   PubMed Web of Science ®Google Scholar
• Kim S, Gupta N, Pevzner PA. Spectral probabilities and generating functions of tandem mass spectra: a strike against decoy databases. J Proteome Res. 2008;7(8):3354–3363.
   PubMed Web of Science ®Google Scholar
• Schnable P, Ware D, Fulton R, et al. The B73 maize genome: complexity, diversity, and dynamics. Science. 2009;326(5956):1112–1115.
   PubMed Web of Science ®Google Scholar
• Meyers BC, Tingey SV, Morgante M. Abundance, distribution, and transcriptional activity of repetitive elements in the maize genome. Genome Res. 2001;11(10):1660–1676.
   PubMed Web of Science ®Google Scholar
• Jeong K, Kim S, Bandeira N. False discovery rates in spectral identification. BMC Bioinformatics. 2012;13(Suppl 16 (16)):S2.
   PubMed Web of Science ®Google Scholar
• Kent WJ, Fan H, Karolchik D, et al. Exploring relationships and mining data with the UCSC Gene Sorter. Genome Res. 2005;15(5):737.
   PubMed Web of Science ®Google Scholar
• Branca RM, Orre LM, Johansson HJ, et al. HiRIEF LC-MS enables deep proteome coverage and unbiased proteogenomics. Nat Methods. 2014;11(1):59–62.
   PubMed Web of Science ®Google Scholar
• Sheynkman GM, Johnson JE, Jagtap PD, et al. Using Galaxy-P to leverage RNA-Seq for the discovery of novel protein variations. BMC Genomics. 2014;15(1):703.
   PubMed Web of Science ®Google Scholar
• Mayer G, Montecchi-Palazzi L, Ovelleiro D, et al. The HUPO proteomics standards initiative- mass spectrometry controlled vocabulary. Database. 2013;2013:bat009.
   PubMedGoogle Scholar
• Vizcanío JA, Deutsch EW, Wang R, et al. ProteomeXchange provides globally coordinated proteomics data submission and dissemination. Nat Biotechnol. 2014;32(3):223–226.
   PubMed Web of Science ®Google Scholar
• Vizcanío JA, Côté RG, Csordas A, et al. The PRoteomics IDEntifications (PRIDE) database and associated tools: status in. Nucleic Acids Res. 2013;41(d1):1063–1069.
   Web of Science ®Google Scholar
• Goecks J, Nekrutenko A, Taylor J, et al. Galaxy: a comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences. Genome Biol. 2010;11(8):R86.
   PubMed Web of Science ®Google Scholar
• Krishna R, Dong X, Sanderson S, et al. A large-scale proteogenomics study of apicomplexan pathogens—toxoplasma gondiiandNeospora caninum. Proteomics. 2015;15(15):2618–2628.
   PubMed Web of Science ®Google Scholar
• Krzywinski M, Schein J, Birol İ, et al. Circos: an information aesthetic for comparative genomics. Genome Res. 2009;19(9):1639–1645.
   PubMed Web of Science ®Google Scholar
• Thorvaldsdóttir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform. 2013;14(2):178–192.
   PubMed Web of Science ®Google Scholar
• Kim S, Mischerikow N, Bandeira N, et al. The generating function of CID, ETD, and CID/ETD pairs of tandem mass spectra: applications to database search. Mol Cell Proteomics Mcp. 2010;9(12):2840–2852.
   PubMed Web of Science ®Google Scholar
• Eng JK, Jahan TA, Hoopmann MR. Comet: an open-source MS/MS sequence database search tool. Proteomics. 2013;13(1):22–24.
   PubMed Web of Science ®Google Scholar
• Bamford S, Dawson E, Forbes S, et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer. 2004;91(2):355–358.
   PubMed Web of Science ®Google Scholar
• Paik YK, Jeong SK, Omenn GS, et al. The chromosome-centric human proteome project for cataloging proteins encoded in the genome. Nat Biotechnol. 2012;30(3):221–223.
   PubMed Web of Science ®Google Scholar
• Lane L, Bairoch A, Beavis RC, et al. Metrics for the human proteome project—2013-2014 and strategies for finding missing proteins. J Proteome Res. 2014;13(1):15–20.
   PubMed Web of Science ®Google Scholar
• Kumar D, Yadav AK, Kadimi PK, et al. Proteogenomic analysis of Bradyrhizobium japonicum USDA110 using GenoSuite, an automated multi-algorithmic pipeline. Mol Cell Proteomics. 2013;12(11):3388–3397.
   PubMed Web of Science ®Google Scholar
• Jones AR, Siepen JA, Hubbard SJ, et al. Improving sensitivity in proteome studies by analysis of false discovery rates for multiple search engines. Proteomics. 2009;9(5):1220–1229.
   PubMed Web of Science ®Google Scholar
• Holohan C, Van Schaeybroeck S, Longley DB, et al. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714–726.
   PubMed Web of Science ®Google Scholar
• Anderson W. International network of cancer genome projects. Nature. 2010;464(7291):993–998.
   PubMed Web of Science ®Google Scholar
• Yang YX, Sun XF, Cheng AL, et al. Increased expression of HSP27 linked to vincristine resistance in human gastric cancer cell line. J Cancer Res Clin Oncol. 2009;135(2):181–189.
   PubMed Web of Science ®Google Scholar
• Kang HC, Kim IJ, Park JH, et al. Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays. Clin Cancer Res Off J Am Assoc Cancer Res. 2004;10(1):272–284.
   PubMed Web of Science ®Google Scholar
• Huang S, Holzel M, Knijnenburg T, et al. MED12 controls the response to multiple cancer drugs through regulation of TGF-beta receptor signaling. Cell. 2012;151(5):937–950.
   PubMed Web of Science ®Google Scholar
• Lee SY. Proteogenomic characterization of antimicrobial resistance in extensively drug-resistant Acinetobacter baumannii DU202. J Antimicrob Chemother. 2014;69(6):1483–1491.
   PubMed Web of Science ®Google Scholar
• Woo S, Cha SW, Bonissone S, et al. Advanced proteogenomic analysis reveals multiple peptide mutations and complex immunoglobulin peptides in colon cancer. J Proteome Res. 2015;14(9):3555–3567.
   PubMed Web of Science ®Google Scholar
• Halvey PJ, Wang X, Wang J, et al. Proteogenomic analysis reveals unanticipated adaptations of colorectal tumor cells to deficiencies in DNA mismatch repair. Cancer Res. 2014;74(1):387.
   PubMed Web of Science ®Google Scholar
• Bertotti A, Papp E, Jones S, et al. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature. 2015;526(7572):263–267.
   PubMed Web of Science ®Google Scholar
• Ahronian LG, Sennott EM, Van Allen EM, et al. Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations. Cancer Discov. 2015;5(4):358–367.
   PubMed Web of Science ®Google Scholar
• Wiegand KC, Hennessy BT, Leung S, et al. A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation. BMC Cancer. 2014;14:120.
   PubMed Web of Science ®Google Scholar
• Duan Z, Feller AJ, Penson RT, et al. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res. 1999;5(11):3445–3453.
   PubMed Web of Science ®Google Scholar
• Thomsen KG, Lyng MB, Elias D, et al. Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients. Breast Cancer Res Treat. 2015;154(3):483–494.
   PubMed Web of Science ®Google Scholar
• Hansen SN, Ehlers NS, Zhu S, et al. The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells. BMC Genomics. 2016;17:442.
   PubMed Web of Science ®Google Scholar
• Stewart PA, Parapatics K, Welsh EA, et al. A pilot proteogenomic study with data integration identifies MCT1 and GLUT1 as prognostic markers in lung adenocarcinoma. PLoS One. 2015;10(11):e0142162.
   PubMed Web of Science ®Google Scholar
• Kim YI, Lee J, Choi YJ, et al. Proteogenomic study beyond chromosome 9: new insight into expressed variant proteome and transcriptome in human lung adenocarcinoma tissues. J Proteome Res. 2015;14(12):5007–5016.
   PubMed Web of Science ®Google Scholar
• Ahn SM, Jang SJ, Shim JH, et al. Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification. Hepatology. 2014;60(6):1972–1982.
   PubMed Web of Science ®Google Scholar
• Brenner H, Kloor M, Pox CP. Colorectal cancer. The Lancet. 2014;383(9927):1490–1502.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Cervantes A, Nordlinger B, et al. Group EGW. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncology: Official Journal Eur Soc Med Oncol. 2014;25(Suppl 3):iii1–9.
   PubMed Web of Science ®Google Scholar
• Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486(7404):532–536.
   PubMed Web of Science ®Google Scholar
• Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clinical Oncology: Official Journal Am Soc Clin Oncol. 2008;26(10):1626–1634.
   PubMed Web of Science ®Google Scholar
• Sartore-Bianchi A, Martini M, Molinari F, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 2009;69(5):1851–1857.
   PubMed Web of Science ®Google Scholar
• Montagut C, Dalmases A, Bellosillo B, et al. Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer. Nat Med. 2012;18(2):221–223.
   PubMed Web of Science ®Google Scholar
• De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet. Oncol. 2010;11(8):753–762.
   PubMed Web of Science ®Google Scholar
• Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra224.
   Web of Science ®Google Scholar
• Bardelli A, Corso S, Bertotti A, et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 2013;3(6):658–673.
   PubMed Web of Science ®Google Scholar
• Taking pan-cancer analysis global. Nat Genet. 2013:45(11):1263–1263.
   PubMed Web of Science ®Google Scholar
• Ai J, Tang Q, Wu Y, et al. The role of polymeric immunoglobulin receptor in inflammation-induced tumor metastasis of human hepatocellular carcinoma. J Natl Cancer Inst. 2011;103(22):1696–1712.
   PubMedGoogle Scholar
• Wang T, Srivastava S, Hartman M, et al. High expression of intratumoral stromal proteins is associated with chemotherapy resistance in breast cancer. Oncotarget. 2016;7:34.
   Google Scholar
• Hu H, Li S, Cui X, et al. The overexpression of hypomethylated miR-663 induces chemotherapy resistance in human breast cancer cells by targeting Heparin Sulfate Proteoglycan 2 (HSPG2). J Biol Chem. 2013;288(16):10973–10985.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Chen Y, Wang C, et al. Phenylarsine oxide can induce the arsenite-resistance mutant PML protein solubility changes. Int J Mol Sci. 2017;18(2):247.
   Web of Science ®Google Scholar
• Donato MD, Fanelli M, Mariani M, et al. Nek6 and Hif-1α cooperate with the cytoskeletal gateway of drug resistance to drive outcome in serous ovarian cancer. Am J Cancer Res. 2015;5(6):1862–1877.
   PubMed Web of Science ®Google Scholar
• Yılmaz I, Ozkok A, Kostek O, et al. C-reactive protein but not hepcidin, NGAL and transferrin determines the ESA resistance in hemodialysis patients. Ren Fail. 2016;38(1):89–95.
   Web of Science ®Google Scholar
• Diouf B, Cheng Q, Krynetskaia NF, et al. Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells. Nat Med. 2011;17(10):1298.
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–954.
   PubMed Web of Science ®Google Scholar
• Mao M, Tian F, Mariadason JM, et al. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res. 2013;19(3):657–667.
   PubMed Web of Science ®Google Scholar
• Jacobs IJ, Menon U, Ryan A, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. The Lancet. 2016;387(10022):945–956.
   PubMed Web of Science ®Google Scholar
• Jayson GC, Kohn EC, Kitchener HC, et al. Ovarian cancer. The Lancet. 2014;384(9951):1376–1388.
   PubMed Web of Science ®Google Scholar
• Coleman RL, Monk BJ, Sood AK, et al. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol. 2013;10(4):211–224.
   PubMed Web of Science ®Google Scholar
• Griffiths RW, Zee YK, Evans S, et al. Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube. Int J Gynecol Cancer. 2011;21(1):58–65.
   PubMed Web of Science ®Google Scholar
• Sarwal MM, Sigdel TK, Salomon DR. Functional proteogenomics–embracing complexity. Semin Immunol. 2011;23(4):235–251.
   PubMed Web of Science ®Google Scholar
• Tibes R, Qiu YH, Lu Y, et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther. 2006;5(10):2512.
   PubMed Web of Science ®Google Scholar
• Liu X, Gao Y, Lu Y, et al. Oncogenes associated with drug resistance in ovarian cancer. J Cancer Res Clin Oncol. 2015;141(3):381–395.
   PubMed Web of Science ®Google Scholar
• Yan B, Yin F, Wang QI, et al. Integration and bioinformatics analysis of DNA-methylated genes associated with drug resistance in ovarian cancer. Oncol Lett. 2016;12(1):157–166.
   PubMed Web of Science ®Google Scholar
• Harbeck N, Gnant M. Breast cancer. The Lancet. 2016.
   PubMed Web of Science ®Google Scholar
• Gruver AM, Portier BP, Tubbs RR. Molecular pathology of breast cancer: the journey from traditional practice toward embracing the complexity of a molecular classification. Arch Pathol Lab Med. 2011;135(5):544–557.
   PubMed Web of Science ®Google Scholar
• Bravata V, Cammarata FP, Forte GI, et al. “Omics” of HER2-positive breast cancer. Omics. 2013;17(3):119–129.
   PubMed Web of Science ®Google Scholar
• Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–2028.
   PubMed Web of Science ®Google Scholar
• Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. The Lancet. 2012;379(9822):1245–1255.
   PubMed Web of Science ®Google Scholar
• Proteogenomics sheds light on tumors. Cancer Discov. 2014:4(10):1108.
   Google Scholar
• Ellis MJ, Gillette M, Carr SA, et al. Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium. Cancer Discov. 2013;3(10):1108–1112.
   PubMed Web of Science ®Google Scholar
• Polyakova A, Kuznetsova K, Moshkovskii S. Proteogenomics meets cancer immunology: mass spectrometric discovery and analysis of neoantigens. Expert Rev Proteomics. 2015;12(5):1–9.
   PubMed Web of Science ®Google Scholar
• Kang MG, Byun K, Kim JH, et al. Proteogenomics of the human hippocampus: the road ahead ☆. Bba-Proteins Proteom. 2015;1854(7):788–797.
   PubMed Web of Science ®Google Scholar
• Barbieri R, Guryev V, Brandsma CA, et al. Proteogenomics: key driver for clinical discovery and personalized medicine. Adv Exp Med Biol. 2016;926:21–47.
   Google Scholar
• Bragazzi NL, Pechkova E, Nicolini C. Chapter four – proteomics and proteogenomics approaches for oral diseases. Adv Protein Chem Structural Biol. 2014;95(95):125–162.
   PubMed Web of Science ®Google Scholar
• Malmström L, Bakochi A, Svensson G, et al. Quantitative proteogenomics of human pathogens using DIA-MS. J Proteomics. 2016;129:98–107.
   Web of Science ®Google Scholar
• Kim YI, Lee J, Choi YJ, et al. Proteogenomic study beyond chromosome 9: new insight into expressed variant proteome and transcriptome in human lung adenocarcinoma tissues. J Proteome Res. 2015;14(12):5007–5016.
   PubMed Web of Science ®Google Scholar
• Barnidge DR, Tschumper RC, Theis JD, et al. Monitoring M-proteins in patients with multiple myeloma using heavy-chain variable region clonotypic peptides and LC-MS/MS. J Proteome Res. 2014;13(4):1905–1910.
   PubMed Web of Science ®Google Scholar
• Faulkner S, Dun MD, Hondermarck H. Proteogenomics: emergence and promise. Cell Mol Life Sci. 2015;72(5):953–957.
   PubMed Web of Science ®Google Scholar
• Ehmsen S, Hansen LT, Bak M, et al. S100A14 is a novel independent prognostic biomarker in the triple-negative breast cancer subtype. Int J Cancer. 2015;137(9):2093–2103.
   PubMed Web of Science ®Google Scholar